Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates

by Moog C, Dereuddre-Bosquet N, Biedma M, Schmidt S, Decoville T, Mangeot I, Zolla-Pazner S, Vcelar B, Katinger D, Holl V, Le Grand R
Published 2012-09-01

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine

by Giemza E, Cai C, Cope A, Woodrow M, Wiggins R, Fraser C, Cole T, Jeffs S, Lacey CJ, Lewis DJ, Mahmhoud A, Katinger D, Cranage M, Shattock R
Published 2009-10-01

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans

by Katinger D, Wagner A, Luque I, Crespillo S, Conejero-Lara F, Roger M, Martin C, Mouz N, Mourao S, Farsang A, Notka F, Malcolm K, Bosquet N, Le Grand R, Moog C, Cope A, Shattock R, Lewis DJ, El Habib R
Published 2012-09-01